Skip to main content
OpenTrials
Completed

NCT Number: NCT07076732

Beyond Platelet Indices, WBC-to-MPV Ratio in Myocardial Infarction With Non-Obstructive Coronary Arteries (MINOCA) Correlate With Short-Term Rather Than In-Hospital Outcomes

This study aims to evaluate the role of platelet indices and the [White blood cell (WBC) /mean platelet volume (MPV)] ratio in correlation with angiographic profiles of patients diagnosed with myocardial infarction with non-obstructive coronary arteries (MINOCA) to assess their predictive value for short-term clinical outcomes.

Completed

Looking for future studies?

Notify Me

Key information

About this study

Globally, ischemic heart disease remains a significant cause of death, and its prevalence constantly increases. Around 5-15% of acute myocardial infarction (AMI) patients show nonobstructive (<50% stenosis) coronary arteries, named myocardial infarction with nonobstructive coronary arteries (MINOCA).

There are two main phases of inflammation during myocardial infarction: the inflammatory phase and the proliferative phase. The white blood cell (WBC) count and its subtypes have been investigated as potential predictors of cardiovascular outcomes in patients with coronary artery disease (CAD), serving as inflammatory markers.

The mean platelet volume (MPV) is determined in the progenitor cell, the bone marrow megakaryocyte. The platelet volume is found to be associated with cytokines (thrombopoietin, interleukin-6, and interleukin-3) that regulate megakaryocyte ploidy and platelet number and result in the production of larger platelets.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years old.
  • Both sexes.
  • Patients with acute myocardial infarction (AMI). Myocardial infarction with nonobstructive coronary arteries (MINOCA) is diagnosed if a patient fulfilled the AMI criteria in the absence of obstructive coronary arteries (type I: <50% stenosis; or type II: no stenosis) as recommended by the recent American Heart Association statement that introduces an updated definition incorporating the 4th universal MI definition, which by agreement excludes Takotsubo syndrome and myocarditis from the eventual diagnosis of MINOCA.

Exclusion criteria

  • Previous history of MI or coronary revascularization (PCI or bypass surgery) with acute/chronic infection.
  • Autoimmune diseases.
  • Systemic inflammatory disease.
  • Patients on treatment therapy which critically affects inflammatory cell count.
  • Patients with malignancy.
  • Chronic kidney disease.
  • Severe liver disease.
  • Severe anemia.
  • Fever (>38°C).

Treatment and study plan

Coronary Angiography

Other

Coronary angiograms will be acquired digitally for quantification.

SYNTAX Score

Other

Upon retrieval of a version from http://www.syntaxscore.com, the anatomical SYNTAX score will be implemented to numerically evaluate the intricacy of coronary lesions.

Primary outcomes

  1. White blood cell count to mean platelet volume ratio (WMR)

    Time frame: Within 6 hours of symptom onset

    White blood cell count to mean platelet volume ratio (WMR) will be recorded.

Secondary outcomes

  1. Incidence of major adverse cardiovascular events

    Time frame: 1 month post-procedure

    Incidence of major adverse cardiovascular events (MACE) will be recorded.

Sponsors and collaborators

Lead sponsor

Sohag University

Other

Registry information

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 22, 2025
Registry last updated
Mar 13, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.